Peter N. Monk

机构：Immunité et Cancer, University of Sheffield · ORCID：0000-0003-4637-3059

发表论文 179 篇 · 总被引 8364 次 · h-index 48

代表论文

• Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae (2024 · Scientific Reports · 被引 23)
• Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia (2024 · Critical Reviews in Microbiology · 被引 23)
• Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection (2023 · Biomedicine & Pharmacotherapy · 被引 21)
• Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiella pneumoniae infections (2023 · iScience · 被引 20)
• Phage therapy could be key to conquering persistent bacterial lung infections in children (2024 · npj Antimicrobials and Resistance · 被引 19)
• Early treatment of corneal abrasions and ulcers–estimating clinical and economic outcomes (2022 · The Lancet Regional Health - Southeast Asia · 被引 15)